Last updated on April 2019

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)


Brief description of study

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).

Clinical Study Identifier: NCT03614156

Contact Investigators or Research Sites near you

Start Over

Ohwa Mental Clinic

Toshima-ku, Japan
1.25miles

Himorogi Psychiatric Institute

Ichigayatamachi, Japan
2.4miles

Yoyogi Mental Clinic

Shibuya-ku, Japan
3.27miles

Maynds Tower Mental Clinic

Shibuya-ku, Japan
3.3miles

Yoyoginomori Mental Clinic

Shibuya-ku, Japan
3.3miles
6.13miles

Himeno Tomomi Clinic

Shinagawa-ku, Japan
7.32miles
7.91miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.